Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Cyclacel Pharmaceuticals Advances Oral Sapacitabine Pivotal Trial Plan in Hematological Malignancies
BERKELEY HEIGHTS, N.J., Feb. 6, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC), (Nasdaq:CYCCP) announced today progress with a pivotal trial plan for sapacitabine, its oral...
-
BERKELEY HEIGHTS, N.J., Feb. 2, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced today that its President and Chief Executive Officer, Spiro Rombotis,...
-
BERKELEY HEIGHTS, N.J., Jan. 13, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced today that the company has begun treating patients in a Phase 2, open...
-
BERKELEY HEIGHTS, N.J., Nov. 13, 2008 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced today that its President and Chief Executive Officer, Spiro Rombotis,...
-
BERKELEY HEIGHTS, N.J., Nov. 7, 2008 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC), (Nasdaq:CYCCP) announced today that its President and Chief Executive Officer, Spiro Rombotis,...
-
BERKELEY HEIGHTS, N.J., Nov. 6, 2008 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced today financial and operating results for the third quarter of 2008. The...
-
BERKELEY HEIGHTS, N.J., Aug. 7, 2008 (PRIME NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced today that Paul McBarron, Executive Vice President, Finance and COO, will...